Sat.Jul 24, 2021 - Fri.Jul 30, 2021

article thumbnail

Social health: The future of healthcare marketing

Bio Pharma Dive

Approximately 79% of patients look to connect through social media to find answers to their health questions.

Marketing 359
article thumbnail

HCPs use of digital

World of DTC Marketing

SUMMARY: 62% of HCPs spend 3 hours per day accessing digtal resources. More HCPs chose to use smartphones to access digital resources as well and usage has increased when accessing a wide variety of professional content. HCPs increasingly turn to trusted colleagues on digital networks for reliable information. Source: Build Relationships and Personalize Your Interactions With HCPs (Wolters Kluwer).

Doctor 313
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene Therapy and Pharmacokinetics

Camargo

How and When to Incorporate PK Design into Your Gene Therapy Development Plan. Gene therapy, which was in its infancy around 30 years ago, is now becoming a more prominent treatment method in many therapeutic areas, from personalized therapy to mass vaccinations against COVID-19. When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dos

article thumbnail

EU backs approval of Moderna’s COVID-19 vaccine in 12-17 year-olds

Pharma Times

Study in adolescents met it primary endpoint, successfully bridging immune responses to those observed in an efficacy study in adults

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Bluebird preps for split by selling manufacturing plant to well-funded startup

Bio Pharma Dive

The startup manufacturing specialist National Resilience, which raised $800 million when it launched last year, will pay Bluebird $110 million for the North Carolina facility, bringing its North American network up to 10.

article thumbnail

How to choose the right digital agency

World of DTC Marketing

INTRODUCTION: One of the most important factors in your digital initiatives’ success, or failure, is the agency you choose. A lot of agencies are competing for our business. Ensuring you have hired the right one is essential to your brand’s success on both the HCP and consumers’ sides. Many CPG brands are bringing their digital marketing and media buying in-house to reduce costs and ensure that the digital strategies are aligned with key brand insights.

Branding 286

More Trending

article thumbnail

A Rationally Designed Therapeutic Vaccine for Herpes

BioSpace

The designation was awarded for RVx201, a live-attenuated therapeutic vaccine the company is developing for genital herpes resulting from the herpes simplex type 2 (HSV-2) virus.

article thumbnail

A biotech startup raises $117M to deliver gene therapies in a new way

Bio Pharma Dive

Flagship Pioneering, the biotech incubator that created Moderna, is helping fund Ring Therapeutics, a startup hoping to disrupt gene therapy development through the use of a different viral vector.

article thumbnail

Researchers find extending the time between Pfizer doses boosts antibodies

Pharma Times

Eight weeks between doses is the 'sweet spot' according to researchers

Antibody 137
article thumbnail

Rapid COVID immune status test launched in UK, Ireland

pharmaphorum

You’ve had your two COVID-19 jabs, but are you actually protected against infection? That’s a question that a fingerprick test launched today in the UK and Ireland could help to answer. The test – originally developed by US manufacturer Chembio Diagnostics – has been introduced into the UK and Irish markets by Guilford-based Luas Diagnostics and tests for the presence of SARS-CoV-2-targeting antibodies in the blood.

Antibody 137
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

AstraZeneca and mRNA COVID-19 vaccines ‘show similar safety profiles’

BioPharma Reporter

A study of more than a million vaccinated people has found 'similar safety profiles' for the AstraZeneca and Pfizer/BioNTech vaccines: adding the incidence of rare blood clots was far higher among people with COVID-19 than those who had received either vaccine.

article thumbnail

A pharma merger's impact ripples across West Virginia as Viatris plant closes

Bio Pharma Dive

One of the country's oldest and largest drug manufacturing plants will shut down Saturday, a casualty of the 2019 merger between Mylan and Pfizer's Upjohn unit. The impact will be felt by a West Virginia city for years to come.

article thumbnail

Four-drug combo therapy shows benefit for newly-diagnosed myeloma patients

Pharma Times

Combo therapy includes carflizomib administered alongside lenalidomide, dexamethasone and cyclophosphamide

Drugs 137
article thumbnail

Google’s DeepMind puts human proteome online for free

pharmaphorum

The most complete database of protein structures ever assembled, developed with the help of Google’s artificial intelligence unit DeepMind, has been made freely available to researchers around the world. DeepMind partnered with the European Molecular Biology Laboratory (EMBL) to come up with the AlphaFold database, which predicts the three-dimensional structures of the human proteome – nearly all (98.5%) of the 20,000 or so proteins expressed by the human genome.

Protein 130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

BioNTech to develop mRNA malaria vaccine; unveils ambitions for Africa vaccine supply

BioPharma Reporter

BioNTech aims to develop the first mRNA-based malaria vaccine, hoping to reach clinical trials by 2022. Meanwhile, it is also exploring possibilities to set up mRNA manufacturing facilities on the African continent â which could potentially be used for vaccines against a wide range of diseases.

article thumbnail

Merck rebounds to win a milestone immunotherapy approval in early breast cancer

Bio Pharma Dive

The FDA reversed an earlier decision to make Keytruda the first immunotherapy available for patients with early-stage breast cancer and also gave the drugmaker a full approval in advanced disease.

338
338
article thumbnail

UK genomics market valued at over £5bn, according to new report

Pharma Times

‘Genomics Nation’ report launched in a bid to showcase the thriving UK genomics sector

Genomics 130
article thumbnail

Why digital doctors are crucial for the future of primary care

pharmaphorum

Our primary care system is weathering a storm on several fronts. Demand is skyrocketing, with GPs delivering millions more appointments than in previous years and workload far outstripping pre-Covid-19 levels. Dr Dan Bunstone explores how innovation can help GPs overcome the current capacity squeeze in primary care and tackle patient backlog. Despite the misconception that general practice has been ‘closed’ during the pandemic, practice staff are supporting a growing number of patients whose l

Doctors 122
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

T Cells: The Forgotten Warrior in the COVID-19 Battle

BioSpace

The T cell response was measured with immunoSEQ® T-MAP™ COVID, a clinical test developed by Adaptive Biotechnologies.

article thumbnail

Bristol Myers withdraws Opdivo in liver cancer as fallout from FDA meeting continues

Bio Pharma Dive

With the decision by Bristol Myers, each of the two accelerated cancer drug approvals an FDA advisory panel voted to overturn in April have now been voluntary withdrawals.

Drugs 334
article thumbnail

Early data shows CanSinoBIO’s inhaled COVID-19 vaccine triggers immune response

Pharma Times

No serious side effects were observed in the Phase I trial

article thumbnail

Tackling the ‘disease of systemic racism’ in clinical trials

pharmaphorum

A lack of racial diversity in clinical trials is a long-standing, well-documented problem that contributes to the stark health inequalities that have been brought into sharp focus by COVID-19. Tackling it, however, has not been easy, thanks in no small part to the reasons being as complex as they are multi-faceted. But, according to the Pharmaceutical Research and Manufacturers of America (PhRMA), the country’s biopharmaceutical companies are “committed to learning and leading” in a bid to “addr

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

8 Best Cities In The US Offering Biotech Jobs

BioSpace

Biotech jobs are one of the most promising career paths for people who are into life sciences and those who dream of creating change in the world through developing breakthrough medicines and therapeutics.

article thumbnail

FDA rejects a biotech's kidney drug, but some analysts still see a 'sliver of hope'

Bio Pharma Dive

The agency wants Ardelyx to run another trial to show its drug affects clinical outcomes for patients with chronic kidney disease. Analysts think this could be accomplished, but would take some time.

Drugs 331
article thumbnail

New study provides insight into the pharma industry’s reputation in the UK

Pharma Times

Findings come from a year-long study into the perceptions of the pharma sector in the UK

123
123
article thumbnail

Safety Evaluation of the Second Dose of mRNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose

JAMA Internal Medicine

This case series study examines the safety of second doses of messenger RNA COVID-19 vaccines after first-dose allergic reactions.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Pfizer-BioNTech Vaccine: African Deal, $34 Billion in Sales, and Efficacy Drop

BioSpace

?Pfizer has reported several highlights regarding its mRNA COVID-19 vaccine. As the world deal with rising Delta variant cases, Pfizer-BioNTech is still arguing that a third booster shot will be likely.

article thumbnail

In a first, FDA approves an 'interchangeable' biosimilar for diabetes

Bio Pharma Dive

An injectable insulin from Viatris has become the first-ever biosimilar product that can be directly substituted for a marketed biologic, a long-awaited decision that could put pricing pressure on other diabetes drugs.

article thumbnail

Regeneron, AZ partner on development of novel obesity drugs

Pharma Times

Collaboration will focus on developing small molecule medicines targeting GPR75

article thumbnail

How tech-driven hubs in specialty pharmacy can improve the patient experience

pharmaphorum

The use of specialty drugs in the U.S. has skyrocketed in recent years driven primarily by an increase in chronic condition diagnosis and the number of new medications on the market. Krishnanjan Alaparthi explores how tech-driven hub services can help manage the complexities of specialty pharma. It’s estimated specialty medications account for 75% of the approximately 7,000 prescription drugs currently in development, and by 2022, more than 60% of the 600 drugs expected to gain FDA approval will

Pharmacy 111
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.